Alpha-2 adrenergic agonists
Alpha-2 adrenergic agonists has been studied in 1 paper since 2024: 1 observational study in people. The newest paper, Sep 28, 2024: “The association between antiglaucomatous agents and Alzheimer's disease”.
1 paper studies it1 findingUpdated
See all 1 papers on alpha-2 adrenergic agonists
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Glaucoma patients on topical alpha-2 adrenergic agonist monotherapy exhibited a significantly higher AD risk (aHR 1.15, 95% CI = 1.01-1.31) compared to those on beta-blockers.”
- 1 lab in 1 country
- Funders: Asia University and others
- Humans1
What is alpha-2 adrenergic agonists linked with?
1Studies link alpha-2 adrenergic agonists with Alzheimer's disease.
Alzheimer's disease
upin humans1
1 study
Alzheimer's disease
upin humans1
Alpha-2 adrenergic agonists are associated with Alzheimer's disease in humans (Patients with glaucoma; compared with beta-blockers) (aHR 1.15, 95% CI 1.01–1.31).
“Glaucoma patients on topical alpha-2 adrenergic agonist monotherapy exhibited a significantly higher AD risk (aHR 1.15, 95% CI = 1.01-1.31) compared to those on beta-blockers.”
HumansPatients with glaucoma; compared with beta-blockerstopical monotherapyover 90 days
The association between antiglaucomatous agents and Alzheimer's disease
Eye (London, England)